At the *BioSpectrum Asia Excellence Award 2022 held in Singapore on December 2, Seegene's Allplex™ SARS-CoV-2 Assay won the Product of Year 2022 award.

Seegene, which fought against the ever-changing COVID-19 during the global pandemic (2020-2021), has been striving to develop molecular diagnostic products, including the early stages of the new coronavirus beginning and until now when many variants have appeared.

As a result of a quick response in the early stages of COVID-19 beginning, we succeeded in developing a product that can detect four target genes simultaneously which are RdRp, S, and N genes for SARS-CoV-2 and E gene of all sarbecoviruses.

The assay provides results within 2 hours after extraction, with high sensitivity and specificity. The product development is based on Seegene’s proprietary MuDT™ technology, reporting individual Ct value of multiple targets in a single channel.

Allplex™ SARS-CoV-2 Assay has been tested in more than 65 countries over 330 million times during the two years of the global pandemic.

*BioSpectrum Asia: Media integration platform where information related to the bio-science industry in the Asia-Pacific region is actively distributed

Read BioSpectrum Asia article